Review Series: Aspects of Interstitial lung disease: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ?
- 23 January 2011
- journal article
- review article
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 8 (1), 53-82
- https://doi.org/10.1177/1479972310393758
Abstract
The lung is frequently involved in connective tissue diseases (CTDs), although the frequency of lung manifestations varies according to the type of CTD. Interstitial lung diseases (ILD) are frequently seen in CTDs, particularly systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM) and rheumatoid arthritis (RA), accounting for a significant proportion of deaths. A large percentage of patients with CTD-associated ILD has limited and stable disease, not requiring treatment. However, a significant minority has severe and/or progressive disease, necessitating prompt initiation of treatment. CTD-ILD histological patterns include non-specific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP), diffuse alveolar damage (DAD) and lymphocytic interstitial pneumonia (LIP). NSIP is the most common pattern in all CTDs, except for RA, characterized by a higher frequency of UIP. ILD can present acutely or chronically, with acute presentations being more common in systemic lupus erythematosus and PM/DM. Idiopathic pulmonary fibrosis (IPF) is a progressively worsening ILD characterized by inflammation and fibrosis. The characteristic histological pattern of IPF is UIP. Interestingly, a UIP pattern is associated with a significantly better survival in CTD-related disease compared to the idiopathic variety. Prognosis in IPF is dismal, with a median survival since diagnosis of 2-3 years. No treatment regimen has been shown to improve survival in IPF. By contrast, although there have been only two randomized placebo-controlled trials investigating the effect of immunosuppressive treatment in SSc-associated ILD, clinical experience suggests that immunosuppressive drugs in CTD-related ILDs are capable of benefiting a significant proportion of patients, particularly those with certain histological patterns of disease. This review will essentially focus on CTD-associated ILD and will compare aspects of clinical presentation and management to those of IPF.Keywords
This publication has 102 references indexed in Scilit:
- Pulmonary complications of tumor necrosis factor-targeted therapyRespiratory Medicine, 2009
- Interstitial lung disease in polymyositis and dermatomyositisClinical Rheumatology, 2009
- The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvementRheumatology, 2008
- Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization dataArthritis & Rheumatism, 2007
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosusAmerican Heart Journal, 1995
- Humoral Immunity in Polymyositis/DermatomyositisJournal of Investigative Dermatology, 1993
- Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosisArthritis & Rheumatism, 1988
- Arzneimittel-induzierte Alveolitis durch SalazosulfapyridinDeutsche Medizinische Wochenschrift (1946), 1988
- Nifedipine and Thallium-201 Myocardial Perfusion in Progressive Systemic SclerosisThe New England Journal of Medicine, 1986